NZBLOOD
Te Ratonga Toto O Aotearoa

Biotherapies for Life™ CSL Behring

RECONSTITUTION OF PROTHROMBINEX®-VF[1]

Mix2Vial™ instructions

STEP 1

Place WFI vial on a level surface and hold firmly
Pierce the WFI vial

STEP 2

Pull out the package and invert WFI vial

STEP 3

Hold the product firmly on a level surface
Pierce the powder vial
(WFI flows automatically)
Gently swirl until dissolved

INCORRECT CONNECTION METHODS

STEP 4

Unscrew Mix2Vial and WFI vial by turning anti-clockwise

STEP 5

Draw reconstituted product into syringe

WFI = Water for Injection vial.
For detailed instructions on reconstitution and administration, see package insert.

PROTHROMBINEX®-VF
Human Prothrombin Complex

PROTHROMBINEX®-VF
Human Prothrombin Complex

Before prescribing, please review Approved Data Sheet. The Approved Data Sheet can be accessed at www.cslbehring.com.au/nz-pi

PROTHROMBINEX®-VF (human prothrombin complex, powder for injection) contains 500 IU Factor IX, approximately 500 IU Factor II and approximately 500 IU Factor X. **Indications:** Treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment or overdose with vitamin K antagonists, when rapid correction of deficiency is required. Treatment and prophylaxis of bleeding in patients with single or multiple congenital deficiency of factors II, IX, or X when purified specific coagulation factor product unavailable. **Contraindications:** Hypersensitivity or allergy to any constituents of preparation, including heparin or history of heparin-induced thrombocytopenia (HIT). Evidence of active thrombosis or disseminated intravascular coagulation (DIC). See Data Sheet. **Precautions:** High doses may predispose to thrombotic complications or heparin-induced thrombocytopenia. Use in pregnancy, lactation, paediatrics or elderly has not been established. Made from human plasma, may contain infectious agents. Risk of infectious agent transmission reduced by donor screening and dedicated manufacturing procedures. Vaccination should be considered. Results of coagulation tests to be interpreted with care due to presence of antithrombin and heparin. See Data Sheet. **Interactions:** Anti-fibrinolytic agents. See Data Sheet. **Adverse Effects:** Include pulmonary embolism, hypercoagulability, DIC, anaphylactic reaction, thrombosis (including myocardial infarction), rash and injection site reaction. See Data Sheet. **Dosage & Administration:** Acquired deficiency (warfarin reversal): PROTHROMBINEX®-VF 25–50 IU/kg where appropriate as part of an overarching clinical strategy in various clinical settings. See Data Sheet. Congenital deficiency: Therapy dependent on severity of coagulation disorder, location and extent of haemorrhage and patient's clinical condition. Reconstitute and administer intravenously at approximately 3 mL/min. See Data Sheet. Classification: General Sales Medicine. Before prescribing, please review full PROTHROMBINEX®-VF Data Sheet, available at the Medsafe website, www.medsafe.govt.nz or the CSL Behring (Australia) website www.cslbehring.com.au/nz-pi; or from CSL Behring (Australia), 189–209 Camp Road, Broadmeadows, Victoria, Australia, 3047. Based on PROTHROMBINEX®-VF Data Sheet, date of preparation: May 2014. (v07/14).

References: 1. PROTHROMBINEX®-VF Approved Data sheet. Date of most recent amendment: 10 October 2014.

For information:
CSL Behring (Australia) Pty Ltd: For Medical/Technical Inquiries: Phone +61 3 9389 1932. For Customer Service Inquiries: Phone +61 3 9246 5231. E-mail: customerservice@cslbehring.com.au.
Internet: www.cslbehring.com.au or New Zealand Blood Service: 71 Great South Road, Epsom, Auckland, New Zealand. Phone: 09 523 5744, Internet: www.nzblood.co.nz.

NZBLOOD
Te Ratonga Toto O Aotearoa

CSL Behring
Biotherapies for Life™

12745. CSL Behring. PTX15-06-0003a.
Date of preparation: November 2015

CSL Behring (NZ) Limited
666 Great South Road, Penrose,
Auckland, New Zealand
NZBN 94 29041 09849 3